J&J and Aldeyra target drugs for inflammatory diseases. Credit: rawpixel.com on Unsplash.

Johnson & Johnson (J&J) subsidiary Janssen Research & Development has signed a collaborative research agreement with Aldeyra Therapeutics for the development of new drugs to treat systemic inflammatory diseases.

Formed through Johnson & Johnson Innovation, the alliance aims to work on a new therapeutic target class called pro-inflammatory aldehyde mediators.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Aldeyra is reported to have already validated its new drug candidate reproxalap, which belongs to its aldehyde sequestration platform, for anti-inflammatory activity in four Phase II clinical trials.

The latest deal is intended to develop existing reproxalap analogues for treating patients suffering from inflammatory diseases.

“We are pleased to partner with Janssen, a world leader in the discovery and development of therapeutics for inflammatory diseases.”

These analogues include reproxalap ocular of 0.1% and 0.25% strength for dry eye disease, 0.25% and 0.5% for allergic conjunctivitis and 0.5% for non-infectious anterior uveitis, along with 1% reproxalap dermal for sjögren-larsson syndrome.

Aldeyra Therapeutics president and CEO said: “As we are committed to the development of novel therapeutic product candidates for autoimmune and other diseases characterised by systemic inflammation, we are pleased to partner with Janssen, a world leader in the discovery and development of therapeutics for inflammatory diseases.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As per the collaboration agreement, both Aldeyra and Janssen will be involved in research activities that are set to be regulated by a joint scientific review committee.

In addition, Janssen will hold an option to negotiate an exclusive licence related to the compounds that will be developed during the partnership. The option is valid for a specific period and is subject to certain conditions.